As a world-leading service provider of antibody development and generation, Creative Biolabs is ready to provide a whole series of biomarker-specific in vitro diagnostic (IVD) antibody development services. A team of experienced scientists focused on antibody development are pleased to assist you in your project in a timely and cost-effective manner. Here, we introduce our IVD antibody development services targeting the EDN marker.

Eosinophil-Derived Neurotoxin (EDN)

Eosinophil-derived neurotoxin (EDN), an enzyme that in humans is encoded by the RNASE2 gene, is currently drawing much attention as a novel biomarker for the diagnosis and monitoring of asthma. The protein encoded by the RNASE2 gene is found in eosinophil granulocytes. It is closely related to the eosinophil cationic protein (RNASE3) from which it diverged about 50 million years ago after the split between the old world and the new world monkeys. It is relatively neutral and has cytotoxic properties. It is capable of reducing the activity of single-strand RNA viruses in culture through its enzymatic activity. It also serves as an attractant to immune cells. A brief introduction to eosinophilic inflammation and eosinophil degranulation proteins will result in several clinical studies, including EDN’s role in post-bronchiolitis wheezing, childhood asthma, childhood allergic rhinitis (AR), chronic cough and asthma in adults, and EDN monitoring in individual clinical cases.

Structure of the RNASE2 protein. Fig.1 Structure of the RNASE2 protein.

EDN Marker of Asthma

Asthma is associated with increased levels of eosinophils in tissues, body fluids, and bone marrow. Regardless of the asthma phenotype, when eosinophils are activated by infection, allergy or both, they release EDN. Thus, EDN levels can be used in the diagnosis and monitoring of different asthma phenotypes (e.g., asthma, viral wheezing, eosinophilic bronchitis, chronic cough, etc.). Eosinophils are major players in allergic diseases. Therefore, the direct measurement of eosinophilic inflammation is required to diagnose, treat, and monitor patients with asthma.

Elevated levels of EDN and eosinophil cationic protein (ECP) have been noted in asthma patients. Higher levels of EDN and ECP are also associated with exacerbated asthmatic conditions. Thus, EDN, along with ECP, may aid the diagnosis and monitoring of asthma. In terms of clinical utility, EDN level is a more accurate biomarker than ECP when analyzing the underlying pathophysiology of asthma. As a monitoring tool, EDN has shown good results in children with asthma as well as other allergic diseases. In conclusion, EDN may be a novel biomarker for the diagnosis, treatment, and monitoring of asthma/allergic disease.

IVD Antibody Development Service Targeting EDN Marker

IVD antibodies are extensively used in immunodiagnostic tools for disease screening and therapeutic monitoring. Through our role as a leading antibody service provider, Creative Biolabs is well-positioned to develop high-quality anti-EDN antibodies. Besides antibody generation, Creative Biolabs also offers diagnostic immunoassay development services, including feasibility analysis, assay design, assay protocol establishment, assay optimization, and kit production.

Creative Biolabs has successfully completed numerous IVD antibody generation and development projects for clients across the globe. If you are interested in our IVD antibody discovery services, please contact us for more details.


  1. Kim, CK. (2013). “Eosinophil-derived neurotoxin: a novel biomarker for diagnosis and monitoring of asthma.” Korean J Pediatr 56(1): 8-12.

Online Inquiry

*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356

Follow us on:
Copyright ©2011 - 2020 Creative Biolabs.